Prenatal testing for hemophilia A when a mutation has not been identified in the family.
Detects the common inversion mutations within the F8 gene. Approximately 50% of affected males with severe hemophilia A have been shown to have an inversion.
It is recommended that the F8 inversion mutation be confirmed in the affected male or obligate carrier female prior to testing at-risk individuals.
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
CULAF | Amniotic Fluid Culture/Genetic Test | Yes | No |
CULFB | Fibroblast Culture for Genetic Test | Yes | No |
MATCC | Maternal Cell Contamination, B | Yes | No |
_STR1 | Comp Analysis using STR (Bill only) | No, (Bill only) | No |
_STR2 | Add'l comp analysis w/STR (Bill Only) | No, (Bill only) | No |
If amniotic fluid is received, amniotic fluid culture for genetic testing will be added and charged separately. If chorionic villus specimen is received, fibroblast culture for genetic testing will be added and charged separately. For any prenatal specimen that is received, maternal cell contamination studies will be added. A maternal whole blood sample is required to perform this test.
The following algorithms are available in Special Instructions:
Polymerase Chain Reaction (PCR) or Inverse Shifting-Polymerase Chain Reaction (IS-PCR)
Hemophilia A
HA
Factor VIII gene
F8
Intron 22 inversion
Intron 1 inversion
If amniotic fluid is received, amniotic fluid culture for genetic testing will be added and charged separately. If chorionic villus specimen is received, fibroblast culture for genetic testing will be added and charged separately. For any prenatal specimen that is received, maternal cell contamination studies will be added. A maternal whole blood sample is required to perform this test.
The following algorithms are available in Special Instructions:
Varies
Due to the complexity of prenatal testing, consultation with the laboratory is required for all prenatal testing. Prenatal specimens can be sent Monday through Thursday and must be received by 5 p.m. CST on Friday in order to be processed appropriately. All prenatal specimens must be accompanied by a maternal blood specimen. Order MATCC / Maternal Cell Contamination, Molecular Analysis on the maternal specimen.
Advise Express Mail or equivalent if not on courier service
Hemophilia A Patient Information is required, see Special Instructions. Testing may proceed without the patient information, however, the information aids in providing a more thorough interpretation. Ordering providers are strongly encouraged to fill out the form and send with the specimen.
Results will be reported and also telephoned or faxed, if requested.
Submit only 1 of the following specimens:
Specimen Type: Amniotic fluid
Container/Tube: Amniotic fluid container
Specimen Volume: 5-10 mL
Collection Instructions:
2. Discard the first 2 mL of amniotic fluid. If the culture will be performed in conjunction with chromosome analysis and alpha-fetoprotein, a total of approximately 25 mL to 30 mL will be needed for the combined studies.
Specimen Stability Information: Ambient (preferred) <24 hours/Refrigerated
Additional Information:
1. Place the tubes in a Styrofoam container (T329).
2. Fill remaining space with packing material.
3. Unavoidably, about 1% to 2% of mailed-in specimens are not viable.
4. Bloody specimens are undesirable.
5. If the specimen does not grow in culture, you will be notified within 7 days of receipt.
Specimen Type: Chorionic villi
Container/Tube: 15-mL tube containing 15 mL of transport media
Specimen Volume: 20-30 mg
Collection Instructions:
1. Collect specimen by the transabdominal or transcervical method.
2. Transfer the chorionic villi specimen to a Petri dish containing transport medium (T095).
3. Using a stereomicroscope and sterile forceps, assess the quality and quantity of the villi and remove any blood clots and maternal decidua.
Specimen Stability Information: Refrigerated (preferred) <24 hours/Ambient
Specimen Type: Confluent cultured cells
Container/Tube: T-25 flask
Specimen Volume: 2 Flasks approximately 90% confluent
Collection Instructions: Submit confluent cultured cells from another laboratory
Specimen Stability Information: Ambient (preferred) <24 hours/Refrigerated
Additional Information: There will be no culture charge.
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.
Amniotic fluid: 10 mL
Chorionic Villi: 5 mg
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Varies |
Prenatal testing for hemophilia A when a mutation has not been identified in the family.
Detects the common inversion mutations within the F8 gene. Approximately 50% of affected males with severe hemophilia A have been shown to have an inversion.
It is recommended that the F8 inversion mutation be confirmed in the affected male or obligate carrier female prior to testing at-risk individuals.
If amniotic fluid is received, amniotic fluid culture for genetic testing will be added and charged separately. If chorionic villus specimen is received, fibroblast culture for genetic testing will be added and charged separately. For any prenatal specimen that is received, maternal cell contamination studies will be added. A maternal whole blood sample is required to perform this test.
The following algorithms are available in Special Instructions:
Hemophilia A (HA) is due to a deficiency of clotting factor VIII (FVIII). HA is an X-linked recessive bleeding disorder that affects approximately 1 in 5,000 males. Males are typically affected with bleeding symptoms, whereas carrier females generally do not have bleeding symptoms but are at risk of having affected sons. Rarely, approximately 10% of carrier females have FVIII activity levels below 35% and are at risk for bleeding.
Bleeding, the most common clinical symptom in individuals with HA, correlates with FVIII activity levels. FVIII activity levels of <1% are associated with severe disease, 1% to 5% activity with moderate disease, and 5% to 40% with mild disease. In males with severe deficiency, spontaneous bleeding may occur. In individuals with mild HA, bleeding may occur only after surgery or trauma.
FVIII is encoded by the factor VIII (F8) gene. Approximately 98% of patients with a diagnosis of HA are found to have a mutation in F8 (ie, intron 1 and 22 inversions, point mutations, insertions, and deletions). The intron 1 and 22 inversion mutations account for approximately 50% of mutations associated with severe HA. These inversions are typically not identified in patients with mild or moderate HA.
It is recommended that the F8 mutation be confirmed in the affected male or obligate carrier female prior to testing at-risk individuals. Affected males are identified by FVIII activity (F8A / Coagulation Factor VIII Activity Assay, Plasma) and clinical evaluation, while obligate carrier females are identified by family history assessment. If the intron inversion assays do not detect an inversion in these individuals, additional analysis (ie, F8 sequencing) may be able to identify the familial mutation. Of note, not all females with an affected son are germline carriers of a F8 mutation, as de novo mutations in F8 do occur. Approximately 20% of mothers of isolated cases do not have an identifiable germline F8 mutation. Importantly, there is a small risk for recurrence even when the familial F8 mutation is not identified in the mother of the affected patient due to the possibility of germline mosaicism.
Not applicable
An interpretive report will be provided.
Obtaining a medical genetics or hematology (coagulation) consultation prior to ordering is advisable. Molecular genetic or hemophilia center consultation is available for all possible hemophilia A cases and is particularly indicated in complex cases or in situations in which the diagnosis is atypical or uncertain.
This assay detects only F8 intron 1 and 22 inversion mutations. Thus, a negative result does not exclude the presence of other mutations in F8.
The intron 1 and 22 inversion mutations targeted by this assay are found in approximately 50% of individuals with severe hemophilia A; the assay may be uninformative for a number of families.
Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Errors in our interpretation of results may occur if information given is inaccurate or incomplete.
1. Antonarakis SE, Rossiter JP, Young M, et al: Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995;86(6):2206-2212
2. Rossiter JP, Young M, Kimberland ML, et al: Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. Hum Mol Genet 1994;3(7):1035-1039
3. Castaldo G, D'Argenio V, Nardiello P, et al: Haemophilia A: molecular insights. Clin Chem Lab Med 2007;45(4):450-461
4. Oldenburg J, Rost S, El-Maarri O, et al: De novo factor VIII gene intron 22 inversion in a female carrier presents as a somatic mosaicism. Blood 2000;96(8):2905-2906
5. Pruthi RK: Hemophilia: A Practical Approach to Genetic Testing. Mayo Clin Proc 2005;80:1485-1499
Genomic DNA from whole blood or cord blood is digested with Ksp 22 I restriction enzyme, ligated with T4 DNA ligase, and amplified by PCR with primers specific for the F8 intron 22 inversion mutations.(Rosetti LC, Radic CP, Larripa IB, De Brasi CD: Developing a new generation of tests for genotyping hemophilia-causative rearrangements involving int22h and int1h hotspots in the factor VIII gene. J Thromb Haemost 2008;6:830-836)
Genomic DNA from whole blood or cord blood is amplified by PCR with primers specific for the F8 intron 1 inversion mutation.(Bagnall RD, Waseem N, Green PM, Giannelli F: Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood 2002;99[1]:168-174)
Monday through Friday
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
81403
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
F8INP | HA F8 Int 1/22 Inversion, AF or CVS | 82343-5 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
35161 | HA F8 Int 1/22 Reason for Referral | 42349-1 |
35162 | HA F8 Int 1/22 Inversion, AF or CVS | 82343-5 |
35163 | F8INP Interpretation | 69047-9 |
35164 | HA F8 Intron 1/22 Reviewed By | 18771-6 |